Nevro Corp. has submitted a premarket approval supplement to the U.S. FDA seeking a green light for its Senza system to treat chronic pain associated with painful diabetic neuropathy (PDN). This ...
REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...
Next Generation Senza ® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif., Oct. 12, ...
As of April 6, 2023, the average one-year price target for Nevro is $45.39. The forecasts range from a low of $33.33 to a high of $78.75. The average price target represents an increase of 24.42% from ...
REDWOOD CITY, Calif., Aug. 23, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback